Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST StudyJ.F.R. Robertson, Matthew J. Ellis, Antonio Llombart‐Cussac et al.|Journal of Clinical Oncology|2009Cited by 312
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ studyJ.F.R. Robertson, Matthew J. Ellis, Antonio Llombart‐Cussac et al.|Breast Cancer Research and Treatment|2012Cited by 172
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Rebecca Kristeleit et al.|Cancer Discovery|2020Cited by 134
Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-α Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic ShockGordon R. Bernard, Xavier Wittebole, Bruno François et al.|Critical Care Medicine|2013Cited by 85